Keyword: Versant Ventures
The financing tees up Enterprise to take three projects into the clinic and push one of them through a midphase proof-of-concept trial.
Roche snapped up a remyelinating drug candidate for multiple sclerosis from an alliance with Versant that also spawned startup Pipeline Therapeutics.
With Inari's commercial opportunities increasing, it has pulled in its biggest round to date to fuel a sales and marketing push.
The four-year alliance tasks Vividion with discovering drugs that interact with the ubiquitin proteasome system cells used to break proteins apart.
The funding will see Quentis' lead immunotherapy candidate into the clinic in 2019.
Pandion Therapeutics is working on localized treatments for autoimmune and inflammatory disease.
The Minneapolis-based medtech firm is aiming to improve glucose control in diabetics by ablating nerves linked to metabolic organs.
The appointment puts Phil Vickers, Ph.D., in charge of the Celgene-partnered biotech as its lead immuno-oncology asset closes in on the clinic.
New startup biotech Oyster Point Pharmaceuticals came out of stealth today with $22 million led by venture capital firms New Enterprise Associates (NEA) and Versant Ventures.
The round equips a team last seen leading Okairos to a €250 million buyout by GSK to take off-the-shelf neoantigen cancer vaccine into the clinic.